Sign In

Michal Walczak

CSO at Captor Therapeutics

Michał J. Walczak is the Chief Scientific Officer (CSO) at Captor Therapeutics Ltd, a biopharmaceutical company specializing in Targeted Protein Degradation (TPD) technology. He has a robust academic background, having obtained his PhD from the Swiss Federal Institute of Technology in Zurich (ETH Zurich). Additionally, he has studied at the University of Wrocław and the University of Virginia, and completed postdoctoral training at the Friedrich Miescher Institute for Biomedical Research in Basel, which is affiliated with Novartis Institutes for Biomedical Research.13

In his role as CSO, Walczak is responsible for overseeing research and development strategies at Captor Therapeutics. The company focuses on developing novel therapeutics aimed at treating severe conditions such as cancer and autoimmune diseases by targeting "undruggable" molecular targets.23 Under his leadership, Captor has made significant advancements in its pipeline projects, including CT-01 and CT-03, which are currently in IND-enabling studies and show promising efficacy in preclinical models.2

Walczak has also been active in presenting research findings at various conferences, highlighting the potential of TPD to overcome challenges in cancer treatment. For instance, he presented on MCL-1 degraders at the 4th Annual Targeted Protein Degradation Summit in 2021.1 His expertise and contributions are pivotal to Captor's strategic objectives as it aims to transition into a clinical-stage company and expand its presence internationally.2

Related Questions

What are Michal J. Walczak's main responsibilities as CSO at Captor Therapeutics?
How has Michal J. Walczak contributed to the development of Targeted Protein Degradation (TPD) at Captor Therapeutics?
What are the key projects Michal J. Walczak is currently working on at Captor Therapeutics?
Can you provide more details about the presentation Michal J. Walczak gave at the 4th Annual Targeted Protein Degradation Summit?
What is the significance of MCL-1 degradation in cancer treatment according to Michal J. Walczak?
Michal Walczak
Michal Walczak, photo 1
Michal Walczak, photo 2
Add to my network

Location

Basel, Basel, Switzerland